Combination Therapy of Fasudil Hydrochloride and Ozagrel Sodium for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
-
- 中島 進
- 佐賀医科大学脳神経外科
-
- TABUCHI Kazuo
- Department of Neurosurgery, Saga Medical School
-
- SHIMOKAWA Shoko
- Department of Neurosurgery, Saga Medical School
-
- FUKUYAMA Kouzou
- Department of Neurosurgery, Saga Medical School
-
- MINETA Toshihiro
- Department of Neurosurgery, Saga Medical School
-
- ABE Masamitsu
- Department of Neurosurgery, Saga Medical School
この論文をさがす
抄録
Fasudil hydrochloride is a new type of intracellular calcium antagonist, different from the calcium entry blockers that are commonly employed for clinical use. Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. The effectiveness of this combination therapy was investigated by comparison with the outcome of 57 patients previously treated with only ozagrel sodium. The combination therapy was significantly more effective (p < 0.01) in reducing the incidence of low density areas on computed tomography scans, and reduced, but not significantly, the occurrence of symptomatic vasospasm. The combination therapy of fasudil hydrochloride and ozagrel sodium has superior effectiveness over only ozagrel sodium in treating patients at risk of vasospasm after aneurysmal subarachnoid hemorrhage.
収録刊行物
-
- Neurologia medico-chirurgica
-
Neurologia medico-chirurgica 38 (12), 805-811, 1998
一般社団法人 日本脳神経外科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205049508480
-
- NII論文ID
- 110002277489
-
- NII書誌ID
- AN00358613
-
- COI
- 1:STN:280:DyaK1M7mt1ynsg%3D%3D
-
- ISSN
- 13498029
- 04708105
-
- PubMed
- 10063353
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可